MATIS Trial
Cross-source consensus on MATIS Trial from 1 sources and 7 claims.
1 sources · 7 claims
Dosage & preparation
Comparisons
Background
Evidence quality
Where it comes from
Highlighted claims
- MATIS was an adaptive, open-label, three-arm, two-stage randomised controlled trial conducted at five hospitals in England between October 2020 and September 2022. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- At the Stage 1 interim analysis, fostamatinib showed no evidence of benefit and was stopped for futility. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- The trial was halted in September 2022 due to declining COVID-19 hospitalisations driven by mass vaccination, leaving the final analysis substantially underpowered. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Final results are hypothesis-generating only because the trial was substantially underpowered. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- The majority of MATIS participants were enrolled at a single large London teaching hospital, limiting generalisability. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Approximately one-third of participants in each active treatment arm did not complete the 14-day treatment course. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic
- Standard of care evolved substantially over the trial period, complicating between-arm and temporal comparisons. — Multiarm multistage randomised controlled trial of inflammatory signal inhibitors (MATIS) for patients hospitalised with COVID-19 pneumonia during the UK pandemic